1. Introduction

State subsidies and fiscal policy in biotechnology refer to the financial, taxation, investment and economic measures adopted by governments to promote, regulate and control the biotechnology sector.

Biotechnology is a strategically important industry because it contributes to:

Pharmaceutical research and vaccine development.

Genetic engineering and genome editing.

Agricultural biotechnology and genetically modified seeds.

Stem-cell research and regenerative medicine.

Synthetic biology and industrial biotechnology.

Bioinformatics and artificial intelligence-assisted drug discovery.

Public-health preparedness and disease prevention.

Biotechnology research frequently involves high investment, lengthy approval procedures, scientific uncertainty and substantial commercial risks. Private companies may therefore hesitate to invest in early-stage research that could generate significant public benefits.

Governments intervene through grants, tax credits, research subsidies, concessional loans, public procurement, infrastructure funding and investment incentives.

However, state financial support must comply with constitutional requirements, public-finance legislation, competition principles, international trade rules and intellectual-property obligations.

Central legal question: How can a government financially support biotechnology innovation while preventing corruption, market distortion, discriminatory treatment and misuse of public money?

2. Meaning and Nature of State Subsidies in Biotechnology

A state subsidy is a financial contribution or economic advantage provided by a government or public authority to encourage a particular activity, industry, institution or enterprise.

In biotechnology, subsidies may support universities, pharmaceutical manufacturers, agricultural biotechnology companies, research laboratories, vaccine producers and start-up enterprises.

Major forms of biotechnology subsidies

A subsidy can be direct or indirect. Direct subsidies involve the transfer of financial resources, whereas indirect subsidies may involve tax concessions, guarantees, subsidised infrastructure or preferential access to government facilities.

3. Constitutional and Legal Foundations

State subsidies must operate within the constitutional framework governing public expenditure, taxation, equality and administrative accountability.

A. Constitutional authority

In India, important constitutional provisions include:

Article 14: Equality before law and protection against arbitrary distribution of subsidies.

Article 19(1)(g): Freedom to carry on business or profession, subject to reasonable restrictions.

Article 21: Protection of life and personal liberty, relevant to access to healthcare and public-health policy.

Article 265: No tax can be levied or collected except by authority of law.

Article 266: Governs the Consolidated Funds and public accounts.

Article 282: Permits Union or State grants for public purposes, even outside their respective legislative fields.

Articles 292–293: Govern borrowing by the Union and States.

Government biotechnology incentives must therefore have a lawful financial foundation and serve a legitimate public purpose.

B. Public-purpose requirement

Government funding should promote identifiable public objectives, such as:

Affordable medicines and vaccines.

Agricultural productivity and food security.

Scientific research and innovation.

Disease prevention.

Employment and industrial development.

National biotechnology infrastructure.

Environmental sustainability.

A subsidy granted merely to favour politically connected enterprises or private commercial interests without a defensible public purpose may face judicial scrutiny.

4. Fiscal Policy in Biotechnology

Fiscal policy refers to the government's use of taxation, public expenditure, grants, subsidies and borrowing to influence economic activity.

In biotechnology, fiscal policy serves two important purposes:

Promotional purpose: Encouraging scientific innovation, industrial development and private investment.

Regulatory purpose: Ensuring that public financial support is consistent with public health, environmental safety, fair competition and economic accountability.

Short-run supply (SRAS)

Long-run supply (LRAS)

Demand (AD)

2040608010020406080Real GDPPrice level

Expansionary fiscal policy shifts AD right; the new equilibrium has recessionary gap

Fiscal policy

Give feedback

A. Expansionary fiscal policy

Expansionary fiscal policy increases government expenditure or reduces taxation to encourage biotechnology investment.

Examples include:

Increasing public funding for vaccine research.

Providing tax credits for pharmaceutical R&D.

Financing genomic research institutions.

Offering capital grants for biotechnology manufacturing.

Supporting start-ups developing new medicines.

Legal significance: Such measures can reduce research costs and encourage private-sector participation in socially beneficial scientific activities.

B. Contractionary fiscal policy

Contractionary fiscal policy reduces public expenditure or increases taxation to control excessive government spending and economic instability.

In biotechnology, it may involve:

Reducing unnecessary industry subsidies.

Ending ineffective tax concessions.

Recovering misused research grants.

Restricting financial assistance to non-compliant companies.

Reducing funding for projects that fail established safety requirements.

However, withdrawal of subsidies must comply with applicable statutory conditions, contractual obligations and principles of administrative fairness.

5. Indian Legal Framework Governing Biotechnology Subsidies

India uses a combination of industrial policy, research funding, taxation, intellectual-property legislation and public-health programmes to promote biotechnology.

A. Department of Biotechnology

The Department of Biotechnology (DBT), under the Ministry of Science and Technology, supports biotechnology research and development.

Its funding activities include:

Academic research grants.

Biotechnology start-up support.

Public-private research partnerships.

Translational research.

Research infrastructure development.

Institutional capacity building.

The legal challenge is ensuring that public funding is distributed through transparent eligibility criteria and measurable research objectives.

B. Biotechnology Industry Research Assistance Council (BIRAC)

BIRAC supports biotechnology innovation and entrepreneurship.

Its activities include financial and institutional assistance for:

Early-stage biotechnology enterprises.

Medical technology development.

Vaccine research.

Agricultural biotechnology.

Industrial biotechnology.

Commercialisation of scientific discoveries.

Public grants should contain clear conditions relating to eligible expenditure, reporting, intellectual property, project milestones and repayment or recovery where applicable.

C. Production Linked Incentive schemes

India's Production Linked Incentive (PLI) framework provides performance-linked financial incentives in selected manufacturing sectors, including pharmaceuticals.

Its biotechnology implications include support for domestic manufacturing capacity, pharmaceutical innovation and the development of critical healthcare supply chains.

An important distinction is that not every pharmaceutical incentive is automatically a biotechnology subsidy. Its legal classification depends on the actual beneficiary, financial contribution, conditions and economic benefit.

D. Taxation and research incentives

Relevant legislation includes:

Income-tax Act, 1961, particularly the provisions governing eligible business deductions, research expenditure and approved donations.

Companies Act, 2013, concerning corporate social responsibility and qualifying research activities.

Customs and GST legislation governing applicable treatment of research equipment, laboratory inputs and biotechnology products.

Appropriation legislation governing the expenditure of public funds.

Tax incentives must be supported by legislation. Article 265 prevents the imposition or collection of taxes without legal authority.

6. Major Case Laws on State Subsidies and Fiscal Policy

The following judgments establish principles relevant to biotechnology subsidies, even where the disputes themselves concerned taxation, government contracts, public resources or economic policy rather than biotechnology.

Case 1: Kasinka Trading v. Union of India (1995)

Citation: (1995) 1 SCC 274.

Legal principle: Withdrawal of tax exemptions and fiscal concessions.

The Supreme Court considered the government's withdrawal of a customs-duty exemption.

The Court recognised that the government may withdraw an exemption in the public interest, subject to the relevant legal framework.

Application to biotechnology:

Suppose the Indian government grants customs concessions for importing advanced gene-sequencing equipment. If fiscal or economic circumstances subsequently justify withdrawal, the government may have authority to change the concession.

However, the decision must be consistent with the governing notification and applicable law.

Significance: Biotechnology enterprises cannot necessarily assume that every tax concession will continue indefinitely.

Case 2: Motilal Padampat Sugar Mills Co. Ltd. v. State of Uttar Pradesh (1979)

Citation: (1979) 2 SCC 409.

Legal principle: Promissory estoppel against the government.

The Supreme Court recognised that government promises may, in appropriate circumstances, create enforceable expectations where a person has relied upon them.

Application to biotechnology:

Suppose a government announces a long-term financial incentive for biotechnology manufacturing. A company invests substantial capital in reliance on that representation.

If the government subsequently changes its position, the company may invoke promissory estoppel, depending on the terms of the promise, the applicable law and any overriding public interest.

Significance: Government subsidy programmes must be administered consistently and responsibly.

Case 3: Ramana Dayaram Shetty v. International Airport Authority of India (1979)

Citation: (1979) 3 SCC 489.

Legal principle: Article 14 and non-arbitrary distribution of public opportunities.

The Supreme Court held that public authorities cannot distribute government opportunities through arbitrary or discriminatory decisions.

Application to biotechnology:

Suppose DBT or another public authority awards a research grant exclusively to a favoured biotechnology company despite other eligible applicants.

Such a decision may be challenged if the selection process violates published criteria, equality principles or the requirement of non-arbitrariness.

Significance: Public biotechnology grants must be awarded through fair, objective and transparent procedures.

Case 4: BALCO Employees' Union v. Union of India (2002)

Citation: (2002) 2 SCC 333.

Legal principle: Judicial restraint in economic policy decisions.

The Supreme Court recognised that courts ordinarily do not substitute their economic-policy preferences for those of the government, provided the policy does not violate constitutional or statutory requirements.

Application to biotechnology:

Government decisions concerning pharmaceutical incentives, vaccine-manufacturing support and biotechnology investment programmes generally involve economic and scientific considerations.

Courts ordinarily respect policy choices but may intervene where there is illegality, arbitrariness, mala fides or constitutional infringement.

Significance: Biotechnology fiscal policy receives a degree of judicial deference, not immunity from judicial review.

Case 5: Natural Resources Allocation, In re, Special Reference No. 1 of 2012

Citation: (2012) 10 SCC 1.

Legal principle: Allocation of public resources and constitutional fairness.

The Supreme Court explained that auction is not a constitutionally mandatory method for allocating every public resource. The government must select a method consistent with constitutional principles and the purpose of the allocation.

Application to biotechnology:

Government allocation of publicly funded laboratory facilities, research infrastructure, biotechnology parks and research opportunities need not invariably follow an auction model.

However, the allocation must satisfy fairness, transparency and public-interest requirements.

Significance: Biotechnology infrastructure and public research resources must be distributed through constitutionally defensible procedures.

Case 6: Modern Dental College and Research Centre v. State of Madhya Pradesh (2016)

Citation: (2016) 7 SCC 353.

Legal principle: Proportionality and reasonable regulation.

The Supreme Court examined the relationship between private institutional autonomy and regulatory measures in professional education.

Application to biotechnology:

Government funding conditions may impose requirements relating to research quality, institutional accountability, laboratory standards and public-interest objectives.

Such conditions should have a legitimate purpose and must be proportionate to the regulatory objective.

Significance: Financial assistance does not eliminate the government's authority to impose lawful regulatory conditions.

Case 7: Union of India v. International Trading Co. (2003)

Citation: (2003) 5 SCC 437.

Legal principle: State policy must satisfy Article 14.

The Supreme Court emphasised that government policy cannot be arbitrary or unreasonable.

Application to biotechnology:

If a government changes eligibility criteria for pharmaceutical research grants without a rational justification, affected enterprises may challenge the decision.

Significance: Biotechnology subsidy policies must be based on intelligible and defensible criteria.

Case 8: State of Punjab v. Nestle India Ltd. (2004)

Citation: (2004) 6 SCC 465.

Legal principle: Government representations and promissory estoppel.

The Supreme Court considered the enforceability of governmental representations concerning tax concessions.

Application to biotechnology:

A biotechnology manufacturer investing in a state after receiving a clear government tax-incentive assurance may seek legal protection if the government subsequently acts inconsistently with that assurance.

The outcome depends on the nature of the representation, legal authority and public-interest considerations.

7. International Case Laws on Subsidies and Biotechnology

International trade law is particularly important because biotechnology products, vaccines, pharmaceuticals and genetically modified agricultural products are traded across national borders.

Case 9: Canada – Aircraft (1999)

Citation: WTO, Canada – Measures Affecting the Export of Civilian Aircraft, WT/DS70/AB/R.

Legal principle: Financial contribution and benefit under the WTO Subsidies and Countervailing Measures Agreement.

The WTO Appellate Body examined whether government financial assistance conferred a benefit upon the recipient.

Application to biotechnology:

If a government provides a biotechnology company with concessional loans, equity investments or financial guarantees, the relevant question is whether the company receives an economic advantage compared with appropriate market conditions.

The existence of government funding alone does not establish every element of a WTO subsidy claim.

Significance: Biotechnology financial support must be evaluated according to the actual economic benefit and the applicable WTO requirements.

Case 10: United States – FSC (2000)

Citation: WTO, United States – Tax Treatment for Foreign Sales Corporations, WT/DS108.

Legal principle: Export-related tax advantages and international subsidy disciplines.

The WTO examined US tax provisions that provided preferential treatment connected with export income.

Application to biotechnology:

A government cannot assume that a tax concession is internationally lawful merely because it is structured as a tax measure.

For example, a tax incentive specifically conditional upon exporting biotechnology products may attract scrutiny under the WTO subsidy rules.

Significance: Biotechnology tax policy must distinguish legitimate domestic R&D incentives from prohibited export-contingent support.

Case 11: European Communities – Measures Affecting the Approval and Marketing of Biotech Products (2006)

Citation: WTO, WT/DS291, WT/DS292 and WT/DS293.

Legal principle: International regulation of biotechnology products.

The WTO Panel examined disputes concerning the European Communities' approval and marketing measures for biotechnology products, particularly genetically modified organisms.

This was principally a regulatory dispute, not a judgment establishing the legality of biotechnology subsidies.

Application to biotechnology:

Government-funded agricultural biotechnology programmes must be distinguished from regulatory approval requirements. Financial support cannot substitute for scientific risk assessment or compliance with applicable biosafety requirements.

Significance: Economic promotion and biotechnology safety regulation must operate as separate but coordinated legal systems.

8. WTO Legal Restrictions on Biotechnology Subsidies

The principal international instrument is the Agreement on Subsidies and Countervailing Measures (SCM Agreement).

World Trade Organization+1

A. Article 1: Definition of subsidy

A subsidy may exist where there is:

Direct transfer of government funds.

Government loans or equity investments.

Loan guarantees.

Government revenue foregone through tax credits or exemptions.

Government provision of goods or services.

Government purchases that confer a benefit.

Accordingly, biotechnology tax credits, research grants and subsidised laboratory facilities may fall within the definition, depending on the facts.

B. Article 2: Specificity

A subsidy is subject to the SCM Agreement's disciplines where it is specific to certain enterprises, industries or groups.

For example, a subsidy restricted to selected pharmaceutical manufacturers may be specific.

A generally available tax measure is not automatically a specific subsidy.

C. Article 3: Prohibited subsidies

Two principal categories are prohibited:

Subsidies contingent upon export performance.

Subsidies contingent upon the use of domestic goods instead of imported goods.

For example, a biotechnology manufacturing grant expressly requiring the recipient to export a specified proportion of its products could raise Article 3 concerns.

Similarly, an incentive requiring companies to use domestic laboratory equipment instead of imported equipment may raise local-content concerns.

D. Articles 5–7: Actionable subsidies

Other specific subsidies may be challenged if they cause adverse effects to another WTO member.

These effects include:

Injury to another country's domestic industry.

Nullification or impairment of trade benefits.

Serious prejudice to another member's interests.

E. Countervailing duties

Under Articles 10–23, importing countries may investigate subsidised imports and impose countervailing duties where the applicable requirements, including subsidisation, injury and causation, are established.

Important qualification: The SCM Agreement originally contained temporary provisions for certain non-actionable subsidies, including specified R&D assistance under Article 8. Those provisions expired in 2000. They should not be treated as a presently available blanket exemption for biotechnology research funding.

World Trade Organization+2

9. European Union Approach to Biotechnology State Aid

The European Union regulates government financial assistance through Articles 107–109 of the Treaty on the Functioning of the European Union (TFEU).

Article 107(1) generally prohibits state aid that distorts or threatens to distort competition and affects trade between Member States, subject to applicable exceptions.

The European Commission's 2022 Research, Development and Innovation Framework provides conditions under which R&D assistance may be compatible with the internal market.

European Commission+1

Relevant biotechnology activities include:

Pharmaceutical R&D.

Clinical research.

Advanced biotechnology infrastructure.

Research partnerships.

Innovation clusters.

Small and medium-sized biotechnology enterprises.

The European approach attempts to balance innovation funding against the risk of giving selected enterprises an unfair competitive advantage.

10. Public Accountability and Misuse of Biotechnology Subsidies

Government subsidies create legal obligations for both funding authorities and recipients.

A. Financial accountability

Recipients should maintain:

Audited financial statements.

Research expenditure records.

Proper utilisation certificates.

Procurement documentation.

Project milestone reports.

Records of related-party transactions.

B. Scientific accountability

Biotechnology projects should also satisfy relevant scientific and regulatory requirements.

For example, a company receiving public funds for gene therapy research should comply with applicable clinical-trial, biosafety and ethical approval requirements.

C. Recovery of misused grants

A government funding authority may recover money where the recipient:

Submits false research information.

Diverts funds to unrelated activities.

Falsifies expenditure records.

Violates material grant conditions.

Obtains assistance through fraud or misrepresentation.

Recovery must follow the applicable scheme, contract and legal procedure.

D. Intellectual-property ownership

An important issue arises when public funding produces commercially valuable biotechnology inventions.

The funding agreement should address:

Ownership of research results.

Patent filing and prosecution.

Licensing rights.

Public-health access.

Commercialisation obligations.

Revenue-sharing arrangements.

Rights concerning publicly funded research materials.

Public funding does not automatically make every resulting invention government property. Ownership depends on applicable legislation, institutional rules and contractual arrangements.

11. Biotechnology Subsidies and India's BioE3 Policy

India's BioE3 Policy (Biotechnology for Environment, Economy and Employment) provides an important example of government intervention in biotechnology.

The policy focuses on high-performance biomanufacturing and supports the development of bio-based industrial products.

Its priority areas include:

Bio-based chemicals and bioplastics.

Active pharmaceutical ingredients and enzymes.

Functional foods and smart proteins.

Precision biotherapeutics.

Cell and gene therapies.

Climate-resilient agriculture.

DBT and BIRAC are involved in its implementation, including support for start-ups, SMEs, research institutions and shared biomanufacturing infrastructure.

Press Information Bureau+1

Other important Indian funding initiatives

BIRAC's official programmes cover different stages of innovation, from proof of concept to commercialisation.

India Science, Technology & Innovation+2

The Research, Development and Innovation Fund, launched in November 2025, is another important financing initiative. BIRAC is an implementing partner for biotechnology and allied areas under this framework.

RDI+1

12. Major Legal Challenges

State subsidies in biotechnology create several difficult legal and economic questions.

1. Subsidy discrimination

Smaller biotechnology companies may be excluded when funding criteria disproportionately favour established pharmaceutical manufacturers.

2. Market concentration

Excessive subsidies to a few companies may create barriers for new biotechnology enterprises.

3. Intellectual-property conflicts

Disputes may arise over patent ownership when publicly funded research produces commercially valuable inventions.

4. International trade conflicts

Subsidised pharmaceutical and agricultural biotechnology exports may attract countervailing investigations.

5. Fiscal sustainability

Governments must balance research expenditure against competing public priorities.

6. Scientific accountability

Public money should not support biotechnology projects that bypass mandatory safety, ethical or regulatory requirements.

7. Federal coordination

In India, Union and State governments may operate different incentive programmes. Their eligibility conditions, financial commitments and regulatory requirements should be coordinated.

13. Principles for a Legally Sound Biotechnology Subsidy Policy

A properly designed subsidy framework should incorporate the following principles:

Legality: Every grant, tax exemption and financial incentive must have an appropriate legal basis.

Transparency: Eligibility and selection criteria must be published.

Equality: Similarly situated biotechnology enterprises should receive fair treatment.

Scientific merit: Funding decisions should be based on credible scientific evaluation.

Public interest: Subsidies should promote healthcare, food security, environmental protection and innovation.

Proportionality: Financial assistance should be proportionate to the intended objective.

Accountability: Recipients must disclose expenditure and research progress.

Competition neutrality: Government assistance should not unnecessarily exclude competing enterprises.

International compliance: Subsidy programmes must comply with applicable WTO obligations.

Review mechanisms: Governments should periodically evaluate the effectiveness of funding programmes.

14. Important Case Law Summary

15. Conclusion

State subsidies and fiscal policy are essential instruments for developing a competitive, innovative and socially responsible biotechnology industry.

In India, government support through DBT, BIRAC, research grants, industrial incentives and biomanufacturing programmes can encourage scientific innovation, improve healthcare infrastructure and strengthen domestic biotechnology capabilities.

However, government financial assistance must remain subject to constitutional equality, financial accountability, transparent administration, intellectual-property obligations and international trade law.

The Supreme Court's decisions in Ramana Dayaram Shetty, BALCO Employees' Union, Motilal Padampat and Natural Resources Allocation provide important legal principles governing public funding, governmental promises, economic policy and allocation of public resources.

Ultimately, the legal objective is to establish a biotechnology funding system in which public money promotes scientific progress without compromising constitutional governance, fair competition, public welfare or international legal obligations.

16. Important Legal Sources for Further Study

Constitution of India – Articles 14, 19, 21, 265, 266 and 282.

Income-tax Act, 1961.

Companies Act, 2013.

WTO Agreement on Subsidies and Countervailing Measures.

General Agreement on Tariffs and Trade (GATT 1994).

Treaty on the Functioning of the European Union, Articles 107–109.

Department of Biotechnology policies and funding guidelines.

BIRAC grant agreements and programme guidelines.

Useful official resources:

BIRAC – Biotechnology funding programmes

DBT – Research grant portal

India – RDI Fund financing mechanism

WTO – Subsidies and Countervailing Measures Agreement

EU – Research and Innovation State Aid Framework

Research note: Most Indian judgments discussed above are general constitutional and fiscal-law authorities, not biotechnology-specific subsidy decisions. They are applied here by analogy to biotechnology funding disputes. WTO subsidy cases likewise concern the interpretation of trade disciplines rather than direct judicial approval of a biotechnology funding scheme. This distinction is important in academic and legal writing.